Pages that link to "Q51089741"
Jump to navigation
Jump to search
The following pages link to Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prosp (Q51089741):
Displaying 9 items.
- Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. (Q36157233) (← links)
- Strategies for improving the efficacy of donor lymphocyte infusion following stem cell transplantation (Q38660984) (← links)
- Donor lymphocyte infusion after allogeneic stem cell transplantation (Q38842433) (← links)
- Optimizing peripheral blood stem cells transplantation outcome through amend relapse and graft failure: a review of current literature. (Q41336256) (← links)
- Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial (Q50069823) (← links)
- Low-dose alemtuzumab for GvHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia (Q51017254) (← links)
- Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML. (Q53776386) (← links)
- Donor lymphocyte infusion in myeloid disorders (Q88653832) (← links)
- Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT (Q90182584) (← links)